Specifically, we used immunostaining to assess the density of positive glioma cells for two proliferation markers, Ki67 and 5-bromo-2′-deoxyuridine (BrdU, administered i.p. 24 h before sacrifice). This evidence concerns the gene MKI67 and glioma.